For research use only. Not for therapeutic Use.
nor-NOHA monoacetate is a selective and reversible arginase inhibitor. nor-NOHA monoacetate induces apoptosis in ARG2-expressing cells under hypoxia. nor-NOHA monoacetate has anti-leukemic activity. nor-NOHA monoacetate can used in study of endothelial dysfunction, immunosuppression and metabolism[1].
nor-NOHA monoacetate (0.1-1 mM, 72 h) induces apoptosis in a dose-dependent manner under hypoxia (1.5% O2) in K562 cells[1].
nor-NOHA monoacetate (1 mM, 72 h) attenuates hypoxia-mediated resistance towards imatinib in K562 or KCL22 cells[1].
nor-NOHA monoacetate (100 mg/kg, i.v., once time) induces a significant reduction of infarct size in male Sprague-Dawley rats[2].
nor-NOHA monoacetate (100 mg/kg, i.v., once time) increases plasma citrulline and nitrite levels and decreases the ornithine plasma levels in male Sprague-Dawley rats[2].
| Catalog Number | I015053 |
| CAS Number | 2250019-93-1 |
| Synonyms | acetic acid;(2S)-2-amino-4-[[amino-(hydroxyamino)methylidene]amino]butanoic acid |
| Molecular Formula | C7H16N4O5 |
| Purity | ≥95% |
| InChI | InChI=1S/C5H12N4O3.C2H4O2/c6-3(4(10)11)1-2-8-5(7)9-12;1-2(3)4/h3,12H,1-2,6H2,(H,10,11)(H3,7,8,9);1H3,(H,3,4)/t3-;/m0./s1 |
| InChIKey | RYUGHGOGNIYFKU-DFWYDOINSA-N |
| SMILES | CC(=O)O.C(CN=C(N)NO)C(C(=O)O)N |
| Reference | [1]. Ng KP, et al. The arginase inhibitor Nω-hydroxy-nor-arginine (nor-NOHA) induces apoptosis in leukemic cells specifically under hypoxic conditions but CRISPR/Cas9 excludes arginase 2 (ARG2) as the functional target. PLoS One. 2018 Oct 11;13(10):e0205254. [2]. Jung C, et al. Arginase inhibition mediates cardioprotection during ischaemia-reperfusion. Cardiovasc Res. 2010 Jan 1;85(1):147-54. |
